secwatch.observer — SEC 8-K summary
======================================

Issuer:     Grace Therapeutics, Inc. (GRCE)
CIK:        0001444192
Form:       8-K
Filed at:   2023-11-13T23:59:59+00:00
Accession:  0000950170-23-062474
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Acasti Q2 FY2024 net loss falls to $3.3M; first patient dosed in pivotal GTX-104 trial
--------------------------------------------------------------------------------

- Net loss of $3.3M ($0.43/share) vs $5.0M ($0.66/share) in Q2 FY2023; R&D spending cut to $0.4M.
- Cash and cash equivalents $27.0M at Sep 30, 2023, down $0.9M from Mar 31, 2023; $7.5M private placement closed in Sep 2023.
- First patient enrolled in STRIVE-ON Phase 3 trial of GTX-104 for aneurysmal subarachnoid hemorrhage (aSAH).
- GTX-104 NDA submission to FDA on track for first half of 2025.
- Private placement led by ADAR1 Partners; proceeds to fund Phase 3 trial, NDA prep, and working capital.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1444192/000095017023062474/0000950170-23-062474-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1444192/000095017023062474/acst-20231113.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-062474

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer